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INTRODUCTION 
The complement system consists of a group of plasma proteins that play an 
important role in the defense of higher vertebrates against microbial infections.'. * In 
addition, complement and complement-derived peptides participate in inflammatory 
reactions and in the regulation of antibody synthesis by lymphocytes.'-6 C3,d the third 
component of complement, is an essential element in the functioning of both the 
classical and the alternative pathways of complement activation. One of the most 
striking characteristics of C3 is its capacity to interact specifically with a number of 
other proteins, and all the net effects of activation of both the classical and the 
alternative pathways of complement depend upon these interactions of C3 and its 
derivatives: 
-As a substrate C3 interacts with the C3-convertases of the classical and alter- 
native pathways, which cleave it into the inflammatory peptide C3a (M, = 8300) and 
the activated protein C3b (Mr = 171,000). 
-As a constituent C3b participates in the assembly of the C5-convertases of both 
pathways and the alternative-pathway C3-convertase. 
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- C 3 b  is the target of the control proteins P l H  (H) and C3b-inactivator (I) of 
the alternative pathway. 
2 3  and derived peptides interact as ligands with a variety of specific receptor 
proteins on the surface of mast cells, platelets, erythrocytes, monocytes/macrophages, 
and lymphocytes.’-10 
In addition, C3b binds in a nonspecific manner to bacterial and cellular surfaces 
and to immune complexes through the activation of its internal thioester bond.’’-’’ 
One of the main tasks in the biochemical analysis of C3 is to map these interactive 
sites on the amino acid sequence of the polypeptide. This requires knowledge of the 
primary structure of C3. The protein is available in large amounts and can be purified, 
but the complete amino acid sequence has not been determined. Sequencing could be 
performed exclusively on the protein level; however, the analysis would benefit from 
confirmation by sequencing of complementary DNA (cDNA), which reflects the 
sequence of messenger RNA. This article describes the partial nucleotide sequence 
analysis of cloned mouse liver C3 cDNA and the derived amino acid sequences of a 
few selected functional domains of the polypeptide, in particular of the internal 
thioester site. 
MATERIALS AND METHODS 
Double-stranded cDNA was prepared from size-fractionated mouse liver messen- 
ger RNA (mRNA) using reverse transcriptase. After addition of homopolymeric 
extensions with terminal transferase, it was inserted into the pst I restriction site of 
the plasmid pBR 322 and propagated in Escherichiu coli, strain K12-HBlO1, using 
standard procedures. The cloning and the identification of C3 cDNA clones by hybrid- 
promoted translation have been described in Reference 16. DNA sequencing, the 
preparation of a genomic DNA library from strain A mouse liver DNA in the phage 
replacement vector h 1059, and the isolation and characterization of C3 clones were 
performed as described.”-’9 
RESULTS 
The analysis of genomic DNA and cDNA sequences revealed several pieces of 
(a) Both the C3a and C3P subunits are contained in the sequence of a single- 
(b) The order of the subunits in the precursor is: NH,-P-a-COOH. 
(c) The initial translation product of C3 messenger RNA is a molecule, tentatively 
named prepro C3, carrying an extension peptide at its amino terminus, a so-called 
signal or leader peptide.” The complete amino acid sequence of the C3 signal peptide 
has been derived from cDNA and genomic DNA sequences: Met-Gly-Pro-Ala-Ser- 
Gly -Ser-Gln-Leu-Leu-Val-Leu-Leu-Leu-Leu-Leu-Ala-Ser-~r-Pro-Leu-Ala-Leu-Gly. 
In its length, amino acid composition, and sequence this predicted peptide shows 
properties that are frequently found in other signal peptides, including a hydrophobic 
core region of eight amino acid residues.” 
(d) The transition region of the C3P and C3a subunits in the precursor pro C3 
has been analyzed. Unfortunately, no mouse C3 amino acid sequences are known 
which could be compared with the predictions from cDNA sequence data. At present 
comparison can only be made with the known partial amino acid sequences of human 
information about the C3 molecule and its biosynthetic pathways: 
chain precursor protein: pro C3. 
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C3.2’ From this comparison it was suggested that the proteolytic processing of pro 
C3 into the C3a and C3/3 subunits is not a single peptide bond hydrolysis, but a 
multiple-step event. In the transition region the precursor contains four consecutive 
arginine residues which are not found in the mature subunits and which must be 
removed during the maturation process. 
7-- :::- - - -C3R “-1 C 
I I 
I I 1  10 
m o u s e  GAU CUU GAG UGC ACC AAG CCA GCA GCCICGC CGC CGU CGC(UCA GUA CAG UUG AUG M A  AGA AGG AUG GAC AAA GCU GGU 
m o u s e D L E C T K P A A R R R R S V Q L M E R R M D K A G  
r a t  S V Q L M E R R M D K A G  
h u m a n  P A A  S V Q L T E K R M N K V G  
porc S V Q L M E K R M N K L G  
20 30 
mouse CAG UAC ACU GAC AAG GGU CUU CGG AAG UGU UGU GAG GAU GGU AUG CGG GAU AUC CCU AUG AGA UAC AGC UGC GAG CGC 
m o u s e Q Y T D K G L R K C C E D G M R O l P M R Y S C Q R  
h u m a n  K Y P - K E L R K C C E 0 G M R Q N P M R F S C Q R 
r a t  Q Y T D K G L R K C C E D G M R D  I P M K Y S  C Q R  
porc Q Y S - K E L R R C C E H G M R N N P M K F S C Q R  
40 50 60 
CGG GCA CGC CUC AUC ACC CAG GGC GAG AAC UGC AUA AAG GCC UUC AUA GAC UGC UGC AAC CAC AUC ACC AAG CUG CGU m o u s e  
mouse R A  R L I T  Q G E N C 1 K A  F I D  C C N H 1 T K L R 
r a t  R A R L I T Q G E S C K L A F M D C C N Y I T K L R  
h u m a n R T R F I S L G E A C K K V F L D C C N Y  I T E L R  
porc R A Q F I H Q G N A C V K A F L N C C E Y  I A K L R  
70 78 I 
m o u s e  GAA CAA CAC AGA AGA GAC CAC GUG CUG GGC CUG GCC AGGIAGU GAA UUG GAG GAA GAC AUA AUU CCA GAA GAA GAU AUU 
mouse E Q H R R D H V L G L A R I S  E L E E D I I P E E D I 
r a t  E Q H R R D H V L G L  
h u m a n R Q H A R A S H L G L A R S N L D E D I I A E E D l  
A RI 
porc Q Q H s R N K . P  L G L A R I  
I 
C N  
- - c 3 a  - - -cc3a9 - - 
FIGURE 1. Amino acid sequences of C3a and its flanking regions in the precursor pro C3. 
Top: Positions of the COOH terminus (C) of the C3p subunit and the NH, terminus (N) of the 
C3a subunit and the C3a fragment. Middle: First row shows the mouse C3 mRNA sequence 
as derived from the cDNA sequence; second row gives the mouse C3 amino acid sequence as 
predicted from the mRNA (cDNA) sequence; third through fifth rows show amino acid sequences 
of the rat, human, and porcine C3a anaphylatoxins.22-2‘Bottorn: Positions of the COOH terminus 
(C) of C3a and the NH, terminus (N) of C3a’. Reprinted from Domdey et at.. Proc. Natl. Acad. 
Sci. USA 7 9  7619-7623, 1982, with permission. 
(e) The entire amino acid sequence of the inflammatory peptide C3a of mice has 
been determined as well as the following 13 amino acid residues of the NH, terminus 
of the C3a’-chain (FIG. 1). The mouse anaphylatoxin peptide C3a shows strong 
sequence conservation with rat (72/78 residues conserved), human (5  1/77), and por- 
cine (50/77) C3a.” 
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( f )  The cleavage between C3a and C3a’ by the C3-convertases is a single peptide 
bond hydrolysis. All the amino acids found in the precursor at this position become 
part of the active C3a and C3b fragments.”, 2’ 
(9) Significant conservation of the thioester regions of mouse and human C3 was 
observed (35/41 residues, one uncertain residue) (see FIG. 2). All those amino acid 
residues that are shared in this region by human C3 and C4, and which are therefore 
believed to be important,15. *’. 26 are also found in mouse C3 (the boxed residues in 
FIG. 2). The second glutamyl residue in the center of the thioester region, which 
participates in the formation of the thioester bond, was found to be encoded as a 
glutamine. 
DISCUSSION 
The findings summarized here confirm and extend earlier reports about the ex- 
istence of the precursor pro C3 polypeptide and the order of the subunits within pro 
1 10 20 
mouse GUU CAA AUG GCU GAA GAU GCU GUG GAC GGG GAG CGG CUG AAA CAC CUC AUC GUG ACC CCC 
mouse V Q M A E D A V D G E R L K 
human V Q M T E D A V D A E R L K H : 
30 40 
mouse GCC GGC UGU GGG GAA CAG AAC AUG AUU GGC AUG ACA CCA ACA GUC AUU GCG CUA CAC UAC CUG 
mouse A v ] ; m ;  ; ; [-I v I A v human S T V I A V S  
FIGURE 2. Comparison of the amino acid sequences encompassing the internal thioester site 
from murine (predicted from the nucleotide sequence) and human C3.I’ Upper row: Mouse 
mRNA sequence determined from cDNA sequence. Middle row: Mouse amino acid sequence 
predicted from cDNA sequence. Bottom row: Human amino acid sequence. The numbering of 
amino acid residues is according to Thomas et al.” The boxes indicate conserved amino acid 
residues that are identical in human C3, C4, and a,-macroglobulin.’’. ’’ 
C3.27-2y Since C3 is a secreted glycoprotein, it was expected to be initially synthesized 
with an amino-terminal signal peptide. However, a signal peptide had not previously 
been detected at the protein level. It may have escaped detection because most likely 
it is cleaved off during or soon after translation. Therefore the molecule tentatively 
named here prepro C3 may never exist in the cell as a full-length entity containing 
both the signal peptide and the entire pro C3 sequence. However, because the predicted 
signal peptide would have a number of properties that are characteristic for signal 
peptides, it appears highly probable that it indeed exists. This prediction needs to  be 
confirmed at the protein level. Similarly, the existence of the four arginine residues 
in the transition region between C3/3 and C3a needs to be substantiated at  the 
polypeptide level. 
The cloned cDNA sequences coding for the mouse C3a anaphylatoxin are now 
precisely known. This offers the possibility of inserting these sequences into an expres- 
sion vector and of producing mouse C3a in bacteria or in a eucaryotic expression 
system. Moreover, specifically designed variants of the peptide could probably be 
generated by means of genetic engineering. Peptide fragments that mimic the active 
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portion of C3a have recently been synthesized based on the human C3a sequence and 
shown to carry a substantial fraction of the biologic activities of native C3a.4. 30 Since 
the inflammatory and immune regulatory functions of C3a need to be studied in much 
greater detail and because most of these functions can best be studied in mouse model 
systems, mouse C3a and variants thereof may become a valuable tool for these in- 
vestigations. 
Whenever protein sequencing is performed on human C3 and C4 proteins purified 
from plasma, the thioester bond is hydrolyzed. As a consequence, the residue that 
originally had participated in the formation of this bond appears as a glutamyl residue. 
As the formation and hydrolysis of the thioester bond are modifications of the primary 
amino acid sequence, it is difficult to determine the original nature of this residue 
from protein sequence data. The cDNA sequence implies a glutamine residue at this 
position in the original mouse C3 translation product. Several models have been 
formulated for the biosynthesis of this biologically important bond. One of them 
proposes an enzymatic conversion of a glutamyl residue into a pyroglutamyl residue 
as a first step.” If the initial residue is indeed a glutamine, then this model needs to 
be revised. 
Two central questions need to be answered about the biosynthesis of the thioester 
bond: 
(a) What are the primary amino acid sequence requirements for the formation of 
this bond? 
(b) Can the biosynthesis of this bond proceed spontaneously or are enzymatic steps 
involved? 
Cloned C3 cDNA sequences can now be used for studying both of these questions. 
In a first round of experiments, cloned cDNA sequences coding for the few core 
amino acids of the thioester region could be inserted into an expression vector and 
introduced into a eucaryotic expression system (tissue culture cells). The presence of 
the thioester bond in the resulting peptide products could be assayed for by incor- 
poration of radioactive methylamine. If a bond is formed, the coding sequences can 
be modified by site-directed mutagenesis in vitro and amino acid residues that are 
essential for the formation of the bond can be identified. If no bond is formed in the 
first round, the coding sequences inserted into the vector could be progressively 
extended in the second round to include coding sequences for further amino-terminal 
or carboxy-terminal flanking residues of the core region or both. As soon as formation 
of the thioester bond occurs, the essential amino acids can again be identified by 
genetic manipulations of the coding sequences as described above. 
The use of bacterial expression systems could be advantageous for studying whether 
formation of the thioester bond requires modifying enzymes. Bacteria do not possess 
some of the enzyme systems that are involved in post-translational modifications of 
eucaryotic proteins, such as the eucaryotic glycosylating enzymes. They may also not 
possess the enzymes required for the formation of the thioester bond. Therefore, the 
same coding sequence for a peptide containing the thioester region on a vector could 
be brought to expression in both a eucaryotic and a bacterial expression system. If 
the peptide produced in the eucaryotic system possesses the bond and the bacterial 
peptide does not, this would suggest an involvement of enzymatic steps and render a 
spontaneous synthesis unlikely. If, on the other hand, the bacterial product also has 
the bond, then this could indicate either spontaneous synthesis or enzymatic synthesis. 
The problem of identifying the enzymes involved would be greatly simplified, however, 
because bacteria are genetically less complex. The availability of cloned C3 sequences 
now allows us to approach these problems. 
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